Vivan clears UAE approval to launch AI cancer-matching study in Abu Dhabi
What's the deal? Vivan Therapeutics has received all regulatory approvals to begin a clinical registration study of its AI software TuMatch at Burjeel Cancer Institute in Abu Dhabi. The prospective study will evaluate the tool in colorectal cancer patients, enrolling at least 10 people at the site. It will be led by Prof. Humaid Al Shamsi, chief executive officer of Burjeel Cancer Institute.
What's the endgame? TuMatch analyses a patient's tumour genomic profile against Vivan's proprietary drug-response dataset and published clinical evidence, then outputs a ranked set of therapy options for the treating oncologist. The dataset is generated using an in vivo Drosophila "avatar" screening platform developed with Mount Sinai Medical CenterDealroom has a profile for this one. Try Dealroom →. It targets patients who have exhausted or are unlikely to benefit from standard regimens.
Why colorectal cancer? It is among the most commonly diagnosed cancers in the UAE and often presents at a younger age or later stage than in Western populations. "Colorectal cancer is notoriously hard to treat, and particularly challenging for patients with activating KRAS mutations, who often have no effective standard-of-care options left," said Dr Nahuel Villegas, Vivan's chief scientific officer.
The policy angle: Approval marks one of the first regulatory clearances in the Emirate for this class of oncology software, Vivan says. It lands as Abu Dhabi builds a precision-oncology base: its Department of Health launched a genomics-led cancer programme in 2022 and in 2026 introduced updated biomedical-research requirements covering trials of AI solutions.
What's the value? Alongside clinical outcomes, the study is designed to capture health economics and value-based care data. That evidence is intended to support reimbursement talks with payers and inform how AI-enabled decision support is adopted across the UAE health system.
What could go wrong? The study is small, so the approval is mainly an early regulatory and evidence-building step. Outcomes and health-economics data, rather than the clearance alone, will determine whether TuMatch can support treatment decisions, reimbursement, or overseas filings.
The signal: The study situates Vivan within Abu Dhabi's wider drive to attract clinical research, which includes a Department of Health–Novartis trials initiative and Burjeel's separate AI cancer-research collaboration with AvatrialDealroom has a profile for this one. Try Dealroom →. Unlike those programmes and early-stage tie-ups, Vivan says it has approvals for a prospective registration study — a concrete step toward clinical validation for its tool.
Read more: hub71.com
Image credit: Generated with Gemini